Section
This article reviews how genetic profiling and dynamic laboratory markers predict clinical outcomes in advanced systemic mastocytosis treated with KIT inhibitors avapritinib and midostaurin, facilitating optimized treatment strategies.
This comprehensive analysis of 8,553 AML patients reveals diverse RAS mutation patterns, their associations with other genomic alterations, and distinct prognostic implications influenced by the genomic context and treatment modalities, gui
This phase 3 trial demonstrates that a chemotherapy-free regimen combining ponatinib and blinatumomab significantly improves event-free survival over imatinib plus chemotherapy in adults with Philadelphia chromosome-positive acute lymphobla
Two hemophilia A patients developed persistent high-titer FVIII inhibitors following AAV-mediated gene therapy with a bioengineered FVIII transgene despite prior extensive FVIII exposure.
Mitochondrial transfer from pediatric AML blasts to macrophages via tunneling nanotubes induces metabolic and immunosuppressive reprogramming, impairing anti-leukemic immune responses and supporting chemoresistance, revealing potential targ
This case series examines immunosuppressive management and long-term outcomes in nine Japanese patients undergoing single living-donor lobar lung transplantation from the same donor as prior HSCT, revealing viable reduced immunosuppression
PPM1D mutations and overexpression are involved in MPN pathogenesis, with dual PPM1D and HDM2 inhibition emerging as a promising therapeutic strategy, particularly for myelofibrosis patients.
This article explores the differential associations of mosaic chromosomal alterations (mCAs), especially chromosomal loss and mosaic loss of the X chromosome, with systemic sclerosis and its subtypes, revealing phenotype-specific genetic co
Factor XI-targeted antibodies, amrecibart and cenvacibart, offer promising anticoagulation by selectively inhibiting intrinsic coagulation pathways, potentially reducing thrombosis without increasing bleeding risk.
This study provides a comprehensive single-cell immune atlas of multiple myeloma, revealing dynamic tumor microenvironment ecotypes linked to disease progression, immune dysfunction, and treatment response, offering new avenues for precisio
This article reviews current strategies to identify and diagnose carriers of hemophilia and women and girls with the condition, highlighting advances in genetics and laboratory testing alongside practical clinical approaches.
The Cutaneous Lymphoma International Prognostic Index (CLIPI) enhances risk stratification and predicts progression and treatment response beyond conventional staging in advanced mycosis fungoides and Sézary syndrome.
KT-253, a selective MDM2 protein degrader, shows potent elimination of malignant myelofibrosis stem/progenitor cells by enhancing p53 pathway activation, outperforming current MDM2 inhibitors and offering a promising therapeutic advance.
Heavy menstrual bleeding in women with bleeding disorder of unknown cause requires systematic evaluation and multimodal treatment to improve outcomes and quality of life, despite diagnostic and therapeutic challenges.
This study reveals that family history significantly elevates postpartum venous thromboembolism risk in primiparous women, with risk proportional to genetic relatedness and number of affected relatives.
Telomere length serves as an independent prognostic marker for progression-free survival in chronic lymphocytic leukemia patients treated with venetoclax-based regimens, highlighting its role in risk stratification during the modern targete
A phase II trial shows that adding the bispecific antibody glofitamab to polatuzumab-R-CHP achieves a 95% complete response rate and durable remission with minimal cytokine release syndrome in high-risk diffuse large B-cell lymphoma.
This article reviews the KOMET-007 trial evaluating ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated AML, highlighting promising remission rates and manageable safety.
Lisocabtagene maraleucel shows sustained high remission rates and a favorable long-term safety profile in patients with heavily pretreated follicular lymphoma after three years of follow-up, including high-risk subgroups.
This multisite study identifies key clinical predictors including age, sex, BMI, diabetes, and prior neurotoxic treatments that contribute to chemotherapy-induced peripheral neurotoxicity (CIPN), affecting dose tolerance and long-term patie
